Buscopan® compositum

SPASMOLYTIC AND ANALGESIC

Composition
Hyoscine-N-Butylbromide 4 mg/mL
Dipyrone 500 mg/mL

Buscopan® compositum is a combination of the spasmolytic agent Buscopan® (Hyoscine-N-Butylbromide) and the analgesic dipyrone.

Activity
Buscopan® compositum acts in three ways:
- directly as a spasmolytic
- directly as an analgesic
- indirectly as an anti-inflammatory agent

These three actions are interrelated.

Pharmacology
Buscopan® blocks the transmission of the neural stimuli at the intramural ganglia of the hollow abdominal organs, which are innervated by the parasympathetic nervous system. Absorption and distribution studies established that Buscopan® compositum is concentrated in the walls of the hollow abdominal organs causing a spasmolysis. This accounts for the lack of systemic atropine like side effects. Buscopan® remains mainly in the enterohepatic circulation. Dipyrone has central analgesic activity plus a direct effect on the smooth muscle cells, lowering the excitability of the smooth muscle fibres. This latter effect together with dipyrone’s antiinflammatory action enhances the properties of Buscopan®. Dipyrone is well tolerated parenterally.

Clinical Action
Buscopan® compositum is recommended in all conditions of severe pain involving spasm in the gastrointestinal, biliary and urogenital tracts. With intravenous administration pain often recedes before the injection is completed and pain relief is clearly apparent. The injection may be repeated after four hours if necessary. The duration of action is approximately six hours.

Buscopan® compositum brings about relief of colic by abolishing the spasm and relieving the pain ensuring a rapid return to normal peristalsis and intestinal function.

Enteritis associated with scouring quickly debilitates the animal through excessive fluid loss. Buscopan® compositum normalises intestinal tone and function, preventing further fluid loss. Concurrent treatment with an appropriate antibacterial or anthelminthic may be instituted. Clinical reports confirm Buscopan® compositum’s usefulness of colic in horses.
Indications
Assists in the treatment of gastroenteritis.
Spasm of the gastro-intestinal, biliary or urogenital tracts associated with severe pain. Buscopan® compositum relieves both pain and smooth muscle spasm.

Horses
Spasmodic colic, scours, oesophageal obstruction, enteritis with diarrhoea.

Cattle/Calves
Pain with enteritis and digestive disturbance, diarrhoea, oesophageal obstruction, postparturient relief of pain, functional tympanitis.

Pigs
All forms of colic, gastroenteritis, diarrhoea.

Dogs
Colic, gastro-enteritis with diarrhoea, vomiting, spasm of the urogenital tract, pain associated with digestive disturbances, tenesmus, urinary calculi.

In gastro-enteritis Buscopan® compositum can be used in combination with antibiotics, sulphonamides or anthelmintics, as required.

Directions for Use
Horses 20-30 mL intravenously
Cattle 20-30 mL intravenously or intramuscularly
Calves/Pigs 5-10 mL intramuscularly
Piglets 1-2 mL intramuscularly
Dogs 1-2.5 mL subcutaneously or intravenously

Intravenous injections to be given slowly.
The injection may be repeated after 4 hours if necessary.

It is an offence for users of this product to cause residues exceeding the relevant MRL in the New Zealand (Maximum Residues Limits of Agricultural Compounds) Food Standards.

Withholding Period
MEAT: ANIMAL PRODUCING MEAT OR OFFAL FOR HUMAN CONSUMPTION MUST NOT BE SOLD FOR SLAUGHTER EITHER DURING TREATMENT OR WITHIN: HORSES 2 DAYS, CATTLE AND PIGS 14 DAYS OF CESSION OF THE LAST TREATMENT. MILK: INTENDED FOR HUMAN CONSUMPTION MUST BE DISCARDED DURING TREATMENT AND FOR 12 HOURS FOLLOWING THE LAST TREATMENT.

Disposal
Dispose of empty container by wrapping with paper and putting in garbage.

Presentation
100 mL bottle solution for injection

Restricted Veterinary Medicine. No. A3483
See www.foodsafety.govt.nz for registration conditions.

Storage
Store below 30°C (Room Temperature).
Protect from light.
Avoid freezing.

After opening, the colour of the injection solution may change. This does not influence the efficacy.

Distributed by
Boehringer Ingelheim (NZ) Ltd.
Animal Health Division
Level 1, Unit 9
42 Ormiston Road
East Tamaki Auckland